• January 2022, the FDA designated Applaud Medical's Acoustic Enhancer technology as a breakthrough product, according to an announcement. Applaud Medical, a San Francisco-based company, created an Acoustic Enhancer technology for use with ureteroscopy with laser lithotripsy (URS-LL) to divide calcium-based urinary stones that are obstructing or that a urologist or other qualified medical professional determines to pose a significant risk of future hindrance and are at least 6mm in diameter but not larger than 20mm.

• March 2021, Boston Scientific and a Baring Private Equity Asia (BPEA) unit inked a legally binding agreement for Boston Scientific to pay USD 1.07 billion in cash upfront to purchase Lumenis' global surgical business. This acquisition allowed Boston Scientific to expand its kidney stone management products globally.

• June 2020, Olympus Corporation introduced the Soltive Laser System, a new thulium fiber laser application created for soft tissue applications and stone lithotripsy.

In this report, the Urolithiasis Management Devices Market has been segmented by Treatment Type, End Use and Geography.

Urolithiasis Management Devices Market, Segmentation by Treatment Type

The Urolithiasis Management Devices Market has been segmented by Treatment Type into Extracorporeal Shock Wave Lithotripsy (ESWL), Intracorporeal Lithotripsy, Percutaneous Nephrolithotomy and Others.

Extracorporeal Shock Wave Lithotripsy (ESWL)

ESWL leads the treatment segment with a market share of roughly 40%, primarily due to its non-invasive approach and minimal patient downtime. It remains the first-line treatment for small to medium-sized stones that can be easily targeted with external shock waves.

Intracorporeal Lithotripsy

With around 30% market share, intracorporeal lithotripsy is gaining traction for its ability to manage complex and larger kidney stones. This approach employs laser or ultrasonic fragmentation techniques and is often performed via ureteroscopy.

Percutaneous Nephrolithotomy

Accounting for close to 20% of the market, percutaneous nephrolithotomy is the treatment of choice for large and complex renal calculi. Though more invasive, it offers high efficacy in difficult cases where ESWL or ureteroscopy is less effective.

Others

The others segment, making up approximately 10% of the market, includes flexible ureteroscopy and combination procedures. These are increasingly preferred for their versatility in addressing diverse stone types and locations.

Urolithiasis Management Devices Market, Segmentation by Product Type

The Urolithiasis Management Devices Market has been segmented by Product Type into Lithotripters and Ureteroscopes.

Lithotripters

Lithotripters dominate the product segment with a market share of about 60%, thanks to their leading role in non-invasive stone treatment. Used primarily in extracorporeal shock wave lithotripsy (ESWL), they are effective for breaking down small to mid-sized renal stones without surgical intervention.

Ureteroscopes

Ureteroscopes hold close to 40% of the market, driven by their use in minimally invasive endoscopic procedures. The growing demand for flexible and digital ureteroscopes is supported by the need for precision and reduced recovery times in stone management.

Urolithiasis Management Devices Market, Segmentation by End Use

The Urolithiasis Management Devices Market has been segmented by End Use into Hospitals & Clinics and Ambulatory Surgical Centers.

Hospitals & Clinics

Hospitals and clinics dominate the end-use segment with a market share of nearly 70%. Their advantages include comprehensive infrastructure, availability of skilled urologists, and the capacity to handle both complex and routine stone removal procedures within inpatient and outpatient settings.

Ambulatory Surgical Centers

Ambulatory surgical centers make up around 30% of the market. These facilities are gaining popularity due to their lower procedure costs, efficient care delivery, and growing use of minimally invasive urolithiasis treatments that enable same-day patient recovery.

Urolithiasis Management Devices Market, Segmentation by Geography

In this report, the Urolithiasis Management Devices Market has been segmented by Geography into five regions; North America, Europe, Asia Pacific, Middle East and Africa and Latin America.

Global Urolithiasis Management Devices Market Share (%), by Geographical Region, 2024

North America

North America leads the urolithiasis management devices market with a share of approximately 38%. Regional dominance is fueled by the high incidence of kidney stones, advanced treatment facilities, and the presence of key medical device manufacturers.

Europe

Europe holds close to 26% of the global market, supported by robust public healthcare systems and growing awareness of non-invasive stone removal therapies. Countries like Germany, France, and the UK are major contributors.

Asia Pacific

Asia Pacific accounts for around 22% and is projected to grow at the fastest pace. The region benefits from expanding healthcare infrastructure, a rising elderly population, and a growing burden of kidney stone disease in densely populated countries.

With a market share of nearly 7%, the Middle East and Africa are emerging markets. While access to advanced care remains limited, healthcare investments and awareness initiatives are expected to drive future growth.

Latin America

Latin America represents about 7% of the market. Regional growth is driven by increasing urology-related healthcare campaigns, enhanced access to minimally invasive treatments, and steady improvements in public healthcare systems.

This report provides an in depth analysis of various factors that impact the dynamics of Global Urolithiasis Management Devices Market. These factors include; Market Drivers, Restraints and Opportunities Analysis.

Drivers, Restraints and Opportunities Analysis.

Drivers

• Increasing prevalence of kidney stones
• Growing demand for minimally invasive procedures

• Rising awareness about urological disorders - Rising awareness about urological disorders is significantly driving the growth of the urolithiasis management devices market. Public health campaigns, educational initiatives, and increased access to digital health information are helping individuals recognize early symptoms of kidney stones and other urinary tract conditions. This heightened awareness is leading to earlier diagnosis and treatment, thereby increasing the demand for effective stone management technologies.

  Healthcare providers are also emphasizing preventive care and routine urological check-ups, further supporting the market. As patients become more informed about the risks and treatment options for urolithiasis, there is a growing preference for minimally invasive and technologically advanced devices, including lithotripsy and ureteroscopes. This trend is expected to continue fueling the adoption of innovative solutions in urolithiasis care across both developed and emerging regions.

Restraints

• Complex and inconsistent reimbursement policies
• Risk of urinary tract damage and post-procedure complications

• Low awareness and limited infrastructure in developing regions - Low awareness and limited infrastructure in developing regions act as significant restraints on the growth of the urolithiasis management devices market. In many low- and middle-income countries, public knowledge of urological health remains minimal, leading to delayed diagnosis and untreated cases of kidney stones. Additionally, the lack of specialized urology centers, diagnostic equipment, and trained professionals hinders timely and effective management of urolithiasis.
  
  The availability of advanced treatment options such as lithotripsy devices or flexible ureteroscopes is often limited due to inadequate funding, poor healthcare infrastructure, and high device costs. These barriers contribute to a reliance on basic treatment approaches, which may not be sufficient for complex or recurring cases. As a result, the market potential in these regions remains underutilized despite a growing burden of urological disorders.

Opportunities

• Development of innovative urology devices
• Strategic collaborations and partnerships

• Rising adoption of lithotripsy devices - Rising adoption of lithotripsy devices presents a strong opportunity for growth in the urolithiasis management devices market. As healthcare providers increasingly favor minimally invasive procedures, lithotripsy has become a preferred solution for kidney stone treatment due to its ability to offer non-surgical, quick, and effective stone fragmentation. This shift is supported by advancements in extracorporeal and intracorporeal lithotripsy technologies that enhance precision and patient comfort.

  The growing preference for outpatient and day-care procedures further supports the demand for lithotripsy systems, which can often be performed with minimal hospital stay. As awareness increases and hospitals aim to improve treatment outcomes while reducing costs, the market for next-generation lithotripsy devices is expected to expand, especially in regions modernizing their urological care infrastructure.

Key players in Global Urolithiasis Management Devices Market include:

• Boston Scientific Corporation
• Cook Medical
• Olympus Corporation
• C. R. Bard, Inc
• Dornier MedTech
• Richard Wolf GmbH
• Stryker Corporation
• Karl Storz SE & Co. KG
• Medtronic plc
• Coloplast Group

In this report, the profile of each market player provides following information:

• Company Overview and Product Portfolio
• Key Developments
• Financial Overview
• Strategies
• Company SWOT Analysis